Why the study?
Little is known regarding the relationship between coagulation biomarkers and clinical outcomes in patients with AF treated with anticoagulants, particularly DOACs and warfarin.
Do elevated coagulation biomarkers predict worse clinical outcomes in elderly patients with nonvalvular atrial fibrillation treated with anticoagulants?
Do elevated coagulation biomarkers predict worse clinical outcomes in elderly patients with nonvalvular atrial fibrillation treated with anticoagulants?
Elevated coagulation biomarkers (D-dimer, TAT, SFMC) are associated with increased risks of cardiovascular events, death, and major bleeding in elderly patients with nonvalvular atrial fibrillation, with prognostic implications varying by anticoagulant type.
Elevated biomarkers linked to higher risks in anticoagulated elderly AF patients; leaves open incremental prognostic value beyond clinical scores.
Background: Little is known about the relationship between coagulation biomarkers and clinical outcomes in patients with atrial fibrillation (AF) treated with anticoagulants, especially direct oral anticoagulants (DOACs) and warfarin. Objectives: This subcohort study evaluated the association between coagulation biomarkers and clinical outcomes in elderly Japanese patients with nonvalvular AF using the ANAFIE (All Nippon AF In the Elderly) Registry. Methods: Patients with a definitive diagnosis of nonvalvular AF and aged ≥75 years at enrollment were included. At enrollment, biomarker levels for D-dimer, thrombin-antithrombin complex (TAT), prothrombin fragment 1+2 (F1+2), and soluble fibrin monomer complex (SFMC), along with data on anticoagulant use, were recorded. Results: Of the 3,194 patients, 95.1% were using oral anticoagulants (OACs) (71.7% DOACs, 23.4% warfarin). D-dimer, TAT, and F1+2 levels, as well as the proportion of patients with a positive SFMC, were lower among those receiving OACs compared with those not receiving OACs. In the DOAC group, higher levels of D-dimer (≥1.0 μg/mL) and TAT (>3 ng/mL) were significantly associated with increased incidences of cardiovascular (CV) events (stroke, myocardial infarction, cardiac intervention, heart failure, and CV death), all-cause death, and CV death. In the warfarin group, higher levels of D-dimer were significantly associated with increased rates of all-cause death, higher levels of TAT with increased major bleeding, and positive SFMC with increased major bleeding and CV events. Conclusions: Higher levels of coagulation biomarkers were associated with a higher risk of worse clinical outcomes, and the relationships between the coagulation biomarkers and outcomes differed between the DOAC and warfarin groups. (Prospective Observational Study in Late-Stage Elderly Patients with Non-Valvular Atrial Fibrillation All Nippon AF In Elderly Registry-ANAFIE Registry; UMIN000024006).
No takes yet. Share an insight, caveat, or question.
Koretsune et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: